NEW YORK, Dec. 11, 2013 /PRNewswire/ -- Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that Douglas J. Beck C.P.A. joined the company as its Chief Financial Officer where he will manage all financial operations. Mr. Beck has a solid financial, accounting and audit expertise and he serves on the SEC Practice Committee and the Chief Financial Officers Committee for the New York State Society of CPAs. He also has significant prior experience in public accounting including at both Andersen LLP and Eisner Amper LLP.
Mr. Beck brings extensive previous experience in corporate management as chief financial officer of public companies, including two biopharmaceutical companies. From May 2011 to February 2013 Mr. Beck served as CFO at iBio Inc. (NYSE AMEX: IBIO). Previously, in 2005 he was appointed CFO of Lev Pharmaceuticals, Inc. also a publicly traded company where he headed financial planning, financial reporting and accounting. At Lev, he was part of the executive team and was instrumental in the successful sale of the company to ViroPharma Incorporated for $618 million in cash and stock. Shire plc recently announced that they acquired ViroPharma valued at approximately $4.2 billion.
"I am extremely delighted that Doug has joined our company," said Sergio Traversa, CEO of Relmada. "We believe that Mr. Beck is the perfect fit within our strategy at this specific point of time. His expertise with SEC regulations, internal financial controls, audits and corporate finance significantly strengthens Relmada's management team. In addition, Mr. Beck's experience with publicly traded companies includes several financings and a large M&A transaction brings a very valuable skill set to our team. We look forward to a successful journey together."
Mr. Beck is a graduate of Fairleigh Dickinson University where he received a Bachelor of Science degree in accounting in 1983.
About Relmada Therapeutics
Relmada Therapeutics, Inc. is a clinical stage, private biopharmaceutical company with a diversified portfolio of four products and a deep early stage pipeline for the treatment of pain. Relmada's strategy focuses on two complementary pillars: the improvement of proven drug candidates with novel delivery methods and pharmaceutical compositions and the development of d-methadone as an innovative NMDA (N-Methyl-D-aspartate) inhibitor platform.
The Company is currently developing several drug candidates including: LevoCap ER, its abuse resistant, once–a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for diabetic painful neuropathy (DPN); BuCap, its oral dosage form of the opioid analgesic buprenorphine; MepiGel, its FDA Orphan Drug designated topical formulation of the local anesthetic mepivacaine.
Safe Harbor Statement
This release contains forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts are forward‐looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward looking statements. The Company assumes no obligation to update or supplement any forward‐looking statements whether as a result of new information, future events or otherwise.
Visit our website at www.relmada.com
|SOURCE Relmada Therapeutics Inc.|
Copyright©2012 PR Newswire.
All rights reserved